The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

Androgen Receptor Signaling

See how Bayer is investigating androgen receptor signaling across the oncology pipeline

Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.

Androgen Receptor Signaling

  • Androgen receptor signaling occurs through the binding of androgens or alternative ligands to the receptor, which causes translocation of the receptor complex to the nucleus1,2

    •  Once inside the nucleus, the receptor complex binds to response elements controlling androgen-responsive genes such as prostate-specific antigen, modulating gene transcription and expression and potentially leading to uncontrolled tumor cell proliferation and increased cell survival1

Tumor Type

Prostate cancer

Related Compound

Darolutamide

Bayer's Oncology Pipeline Brochure 

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.